HeartBeam, Inc. (BEAT) stock
BEATNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as BEATW
$0.55+0.01 (+2.06%)
Close on Oct 30, 2026Market cap $659.29KP/E –Yield –
HeartBeam r&d expenses
Research and development expenses are spending on new products and technology.
HeartBeam's R&D Expenses for the twelve months ending Jun 30, 2026 was $11.33M, down 10.1% year over year. For fiscal 2025 it was $13.45M, up 21.7% from the year before. The highest annual figure on record is $13.45M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.45M | +21.7% |
| FY2024 | Dec 31, 2024 | $11.05M | +62.6% |
| FY2023 | Dec 31, 2023 | $6.80M | +19.7% |
| FY2022 | Dec 31, 2022 | $5.68M | +2126.3% |
| FY2021 | Dec 31, 2021 | $255.00K | +91.7% |
| FY2020 | Dec 31, 2020 | $133.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.33M | -30.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.37M | -32.1% |
| Q4 FY2025 | Dec 31, 2025 | $3.35M | +16.2% |
| Q3 FY2025 | Sep 30, 2025 | $3.28M | +13.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.33M | +16.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.49M | +43.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.89M | +43.6% |
| Q3 FY2024 | Sep 30, 2024 | $2.89M | +78.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.84M | +91.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.43M | +44.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.01M | +22.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.62M | +3.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.48M | -14.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.68M | +129.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.64M | +1609.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.56M | +1387.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.74M | +6868.0% |
| Q1 FY2022 | Mar 31, 2022 | $734.00K | +2431.0% |
| Q4 FY2021 | Dec 31, 2021 | $96.00K | +104.3% |
| Q3 FY2021 | Sep 30, 2021 | $105.00K | +84.2% |
| Q2 FY2021 | Jun 30, 2021 | $25.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $29.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $47.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $57.00K | – |